A recombinant live attenuated tetravalent vaccine for the prevention of dengue.

about

The bright and the dark side of human antibody responses to flaviviruses: lessons for vaccine design.Recent Developments in Recombinant Protein-Based Dengue Vaccines Clinical Advances in Viral-Vectored Influenza Vaccines

P2860

Q47558217-DFF1043A-B04F-4CA0-8D53-E904921947DB Q56960671-45D605B9-A6E5-43D3-AB7F-37AC83896A35 Q57094631-A63EF71A-34C4-42A0-AC02-A7C4D5F1D6EB

P2860

A recombinant live attenuated tetravalent vaccine for the prevention of dengue.

Item

http://www.wikidata.org/entity/Q38738484

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

A recombinant live attenuated tetravalent vaccine for the prevention of dengue.

@en

type

Item

label

A recombinant live attenuated tetravalent vaccine for the prevention of dengue.

@en

prefLabel

A recombinant live attenuated tetravalent vaccine for the prevention of dengue.

@en

P1476

A recombinant live attenuated tetravalent vaccine for the prevention of dengue.

@en

P2093

Anna Skipetrova

http://www.w3.org/2001/XMLSchema#string

Bruno Guy

http://www.w3.org/2001/XMLSchema#string

Fernando Noriega

http://www.w3.org/2001/XMLSchema#string

François Verdier

http://www.w3.org/2001/XMLSchema#string

Laurent Coudeville

http://www.w3.org/2001/XMLSchema#string

Maïna L'azou

http://www.w3.org/2001/XMLSchema#string

Nicholas Jackson

http://www.w3.org/2001/XMLSchema#string

R Leon Ochiai

http://www.w3.org/2001/XMLSchema#string

Stephen Savarino

http://www.w3.org/2001/XMLSchema#string

Valentine Delore

http://www.w3.org/2001/XMLSchema#string

P2860

The global distribution and burden of dengue

From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine

Safety Overview of a Recombinant Live-Attenuated Tetravalent Dengue Vaccine: Pooled Analysis of Data from 18 Clinical Trials

Benefits and risks of the Sanofi-Pasteur dengue vaccine: Modeling optimal deployment

Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: A randomized, observer-blind, placebo-controlled phase II trial

Tetravalent Dengue Vaccine Reduces Symptomatic and Asymptomatic Dengue Virus Infections in Healthy Children and Adolescents Aged 2–16 Years in Asia and Latin America

A Prospective Nested Case-Control Study of Dengue in Infants: Rethinking and Refining the Antibody-Dependent Enhancement Dengue Hemorrhagic Fever Model

Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial

Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico.

Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever.

P304

1-13

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14760584.2017.1335201

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-06-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28590795

http://www.w3.org/2001/XMLSchema#string

P921

attenuated vaccine

Dengue virus

A recombinant live attenuated tetravalent vaccine for the prevention of dengue.

about

P2860

P2860

A recombinant live attenuated tetravalent vaccine for the prevention of dengue.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921